Original Article

Single Long Stents Versus Overlapping Multiple Stents in the Management of Very Long Coronary Lesions: Comparisons of Procedures and Clinical Outcomes

Abstract

Background: Different percutaneous coronary intervention (PCI) strategies, including the use of single long stents (SLSs) and overlapping multiple stents (OMSs), have been introduced to treat very long coronary lesions (VLCLs). The aim of this study was to compare procedural and long-term clinical outcomes between SLSs and OMSs in patients with VLCLs.
Methods: In this historical cohort study, 1709 patients who underwent PCI with the new generation of drug-eluting stents (length ≥38 mm) were stratified into the SLS [PROMUS /Resolute/XIENCE (PRX), (=38 mm), n=1121 (65.59%) and BioMime, (≥40 mm), n=124 (7.26%)] and OMS [(59.43±10.80 mm), n=464 (27.2%)] groups and followed up for 440.93±361.32 days. The study endpoints comprised immediate post-PCI outcomes, major adverse cardiovascular events (MACE), the patient-oriented composite endpoint (POCE), and the device-oriented composite endpoint (DOCE) at the long-term follow-up.
Results: The mean age of the patients was 59.28±10.60 years, and 69.6% of them were male. Flow grade 3 (P=0.296) and residual stenosis (P=0.533) were statistically similar between all the groups. A lower level of post-PCI troponin was observed in the BioMime group [14.52 (IQR25%-75%:10.44–22.42) ng/L; P=0.031] than in the PRX and OMS groups [18.63 (IQR25%-75%:10.51–34.02) ng/L and 18.96 (IQR25%-75%:11.17–35.34) ng/L; respectively]. Similarly, the PRX and BioMime groups received lower amounts of the contrast agent [206.29±49.15 mL and 208.06±55.23 mL; respectively] than did the OMS group [265.50±74.69 mL; P<0.001]. There were no statistically significant differences in the incidence of MACE [81 (7.2%), 7 (5.6%), and 28 (6.0%); P=0.603], the POCE [141 (12.6%), 13 (10.5%), and 54 (11.6%); P=0.731], and the DOCE [51 (4.5%), 4 (3.2%), and 21 (4.5%); P=0.791] between the PRX, BioMime, and OMS groups, respectively.
Conclusion: In the treatment of VLCLs, the SLS and OMSs appear to have similar clinical outcomes. BioMime ultra-long stents may have comparable results to PRX coronary stents.

Moran AE, Forouzanfar MH, Roth G, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980-2010: The Global Burden of Disease 2010 Study. Circulation. 2014:CIRCULATIONAHA. 113.004042.

De Scheerder IK, Wang K, Kostopoulos K, et al. Treatment of long dissections by use of a single long or multiple short stents: clinical and angiographic follow-up. American heart journal. 1998;136(2):345-51.

Hoffmann R, Herrmann G, Silber S, et al. Randomized comparison of success and adverse event rates and cost effectiveness of one long versus two short stents for treatment of long coronary narrowings. The American journal of cardiology. 2002;90(5):460-4.

Mori N, Okamoto N, Tanaka A, et al. Comparison of Angiographic and 1-Year Outcomes Between a Long Single Stent and Overlapping Double Stents in Patients With Newer-Generation Drug-Eluting Stents for Long Narrowings. The American journal of cardiology. 2016;117(11):1724-8.

Pan M, Suárez de Lezo J, Medina A, et al. Influence of stent treatment strategies in the long‐term outcome of patients with long diffuse coronary lesions. Catheterization and cardiovascular interventions. 2003;58(3):293-300.

Li X-t, Sun H, Zhang D-p, et al. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents. Coronary artery disease. 2014;25(5):405-11.

Dani S, Costa RA, Joshi H, et al. First-in-human evaluation of the novel BioMime sirolimus-eluting coronary stent with bioabsorbable polymer for the treatment of single de novo lesions located in native coronary vessels-results from the meriT-1 trial. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2013;9(4):493-500.

Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. Journal of the American College of Cardiology. 2001;38(7):2114-30.

Members ATF, Hamm CW, Bassand J-P, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European heart journal. 2011;32(23):2999-3054.

Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes. Circulation. 2014:CIR. 0000000000000134.

Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. European heart journal. 2012;33(20):2551-67.

Bouras G, Jhamnani S, Ng VG, et al. Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials. Catheterization and Cardiovascular Interventions. 2017;89(6):984-91.

Aoki J, Ong AT, Granillo GAR, et al. “Full metal jacket”(stented length≥ 64 mm) using drug-eluting stents for de novo coronary artery lesions. American heart journal. 2005;150(5):994-9.

Lee PH, Lee S-W, Yun S-C, et al. Full metal jacket with drug-eluting stents for coronary chronic total occlusion. JACC: Cardiovascular Interventions. 2017;10(14):1405-12.

Räber L, Jüni P, Löffel L, et al. Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation. Journal of the American College of Cardiology. 2010;55(12):1178-88.

O’Sullivan CJ, Stefanini GG, Räber L, et al. Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents. EuroIntervention. 2014;9(9):1076-84.

Seth A, Costa R, Kaul U. Late angiographic and clinical outcomes of the novel BioMime™ sirolimus-eluting coronary stent with ultra-thin cobalt–chromium platform and biodegradable polymer for the treatment of diseased coronary vessels: results from the prospective, multicentre meriT-2 clinical trial. AsiaIntervention. 2016;2:19-27.

Jain RK, Chakravarthi P, Shetty R, et al. One-year outcomes of a BioMime™ Sirolimus-Eluting Coronary Stent System with a biodegradable polymer in all-comers coronary artery disease patients: The meriT-3 study. Indian heart journal. 2016;68(5):599-603.

Valero E, Consuegra-Sánchez L, Minana G, et al. Initial experience with the novel BioMime 60mm-long sirolimus-eluting tapered stent system in long coronary lesions. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2017.

Zivelonghi C, van Kuijk JP, Nijenhuis V, et al. First report of the use of long‐tapered sirolimus‐eluting coronary stent for the treatment of chronic total occlusions with the hybrid algorithm. Catheterization and Cardiovascular Interventions. 2018.

Files
IssueVol 14 No 3 (2019): J Teh Univ Heart Ctr QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/jthc.v14i3.1427
Keywords
Coronary artery diseases Percutaneous coronary intervention Stents Drug-eluting stents
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Amirzadegan A, Hasanabadi M, Saadatagah S, Afarideh M, Omidi N, Aghajani H, Alidoosti M, Poorhosseini H, Salarifar M, Nozari Y. Single Long Stents Versus Overlapping Multiple Stents in the Management of Very Long Coronary Lesions: Comparisons of Procedures and Clinical Outcomes. J Tehran Heart Cent. 2019;14(3):94-102.